Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06470867 · ClinicalTrials.gov registry record · NA
Randomized Controlled Effectiveness Trial of VA S.A.V.E.
A NA study of Suicide Prevention, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- NA
- Development phase
- 710
- Enrollment target
- 1
- Study location
NCT06470867: Recruiting NA study of Suicide Prevention, sponsored by VA Office of Research and Development.
NCT06470867 is a NA study of Suicide Prevention that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 710 participants, below the 919-participant average among 21 other Suicide Prevention trials with a reported enrollment target (23% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06470867, a NA study of Suicide Prevention, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- NA
- Development phase
- 710 participants
- Enrollment target
- 1
- Study location
Study Summary
Veterans are most likely to disclose suicidal thoughts to their close supports such as family and friends. These loved ones are, in turn, very interested in learning how to help a Veteran in need. Close supports are uniquely poised to provide a meaningful contribution to suicide prevention, if they can learn how to effectively promote Veterans' connection to care. VA S.A.V.E. (Signs; Ask; Validate; Encourage) is a suicide prevention gatekeeper training specifically tailored to the Veteran community that teaches close supports how to identify signs of suicide risk and how to connect the at-risk person to professional treatment. The primary objective of this study is to evaluate the effectiveness of VA S.A.V.E. and to explore factors impacting its potential widespread implementation.
Primary Outcome
Number of gatekeeper behaviors used (sum): Gatekeeper behaviors are comprised of three survey items: 1) ask if having suicidal thoughts ("\[In the past month\] how many times did you directly ask a person if they were having suicidal thoughts?"); 2) recommend professional treatment ("How many times did you tell a person having suicidal thoughts to see their doctor, go to the emergency room, call 911, or get any other professional treatment?"); and 3) provide suicide prevention hotline informatio
Conditions Studied
Interventions
- BEHAVIORAL VA S.A.V.E.
- BEHAVIORAL Control training
Study Locations (1)
Oregon
- VA Portland Health Care System, Portland, OR - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 710 participants |
| Start Date | 2024-11-21 |
| Est. Completion | 2028-03-31 |
| Phase | NA |
What NCT06470867 shows while recruiting
NCT06470867 is an interventional study that assigns participants to a tested intervention. The registered 710 participants enrollment target is mid-sized for trials with a published cap, below the 919-participant average among 21 other Suicide Prevention trials with a reported enrollment target (23% lower).
The record links to 1 condition, with Suicide Prevention appearing as the primary indexed condition, and to 2 interventions - of which VA S.A.V.E. is the first listed.
NCT06470867 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT06470867 about?
NCT06470867 is a clinical study titled "Randomized Controlled Effectiveness Trial of VA S.A.V.E.". Veterans are most likely to disclose suicidal thoughts to their close supports such as family and friends. These loved ones are, in turn, very interested in learning how to help a Veteran in need. Close supports are uniquely poised to provide a meaningful contribution to suicide prevention, if they ...
What is the current status of trial NCT06470867?
This trial is currently recruiting. It is a NA study. The enrollment target is 710 participants. The study started on 2024-11-21. Estimated completion is 2028-03-31.
What conditions does trial NCT06470867 study?
This clinical trial studies the following conditions: Suicide Prevention.
What interventions are being tested in trial NCT06470867?
The interventions under investigation include: VA S.A.V.E. (BEHAVIORAL), Control training (BEHAVIORAL).
Who is sponsoring clinical trial NCT06470867?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06470867 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Suicide Prevention
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06470867's enrollment target sits among peer trials
710 8th of 21 higher than 14 of 21 other Suicide Prevention trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Suicide Prevention trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Project Safe Guard-Trauma
RECRUITING · NA
-
Virtual Reality Lethal Means Safety Training
RECRUITING · NA
-
Efficacy-Implementation Study for PC CARES in Rural Alaska
RECRUITING · NA
-
Syncing Screening and Services for Suicide Prevention Across Health and Justice Systems
RECRUITING · NA
-
Suicide Prevention After Community Care Discharge
RECRUITING · NA
-
HAVEN-Connect Youth Suicide Prevention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06179160 · 710 participants · Phase 1
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- NCT06235697 · 710 participants · Phase 3
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
- NCT07022483 · 710 participants · Phase 3
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
- NCT05208762 · 714 participants · Phase 1
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI